Immunohistochemical analysis of hormone receptors and proliferating cell nuclear antigen in aggressive angiomyxoma of the vulva

Rotmensch, E.J.; Kasznica, John; Mohammadjafari, Hamid

doi:10.1016/0020-7292(93)90701-w

Cited by 26 publications

(13 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…3 In addition, other reports have demonstrated ER and/or PR positivity within aggressive angiomyxoma. [3][4][5][6][7] In our study, all five females patients showed positivity for ER, staining being weak or moderate in intensity. Four or five cases were strongly positive for PR throughout most of the tumour.…”

Section: Discussionsupporting

confidence: 54%

“…3 In addition, several reports have demonstrated oestrogen receptor (ER) and/or progesterone receptor (PR) positivity within this neoplasm, either by immunohistochemistry or by direct assay. [3][4][5][6][7] The aim of our study was to investigate the ER and PR status of six cases of aggressive angiomyxoma, including one in a male patient. We wished to determine whether this would be of value in the distinction between aggressive angiomyxoma and a variety of lesions that can mimic it.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Aggressive angiomyxoma of pelvic parts exhibits oestrogen and progesterone receptor positivity

McCluggage¹,

Patterson²,

Maxwell³

2000

Journal of Clinical Pathology

115

View full text Add to dashboard Cite

Aims-Aggressive angiomyxoma of pelvic parts is a distinctive soft tissue tumour that chiefly involves the vulvar and perineal region of female patients. Several previous reports have demonstrated oestrogen receptor (ER) and/or progesterone receptor (PR) positivity in this neoplasm. The aim of this study was to confirm whether ER and/or PR positivity is present in aggressive angiomyxoma. We also wished to ascertain whether positivity may be found in the stromal cells of normal vulval skin and in other lesions at this site that can cause diagnostic confusion with aggressive angiomyxoma. Methods-Five aggressive angiomyxomas in female patients and one involving male pelvic soft parts were stained immunohistochemically with antibodies against ER and PR. Other samples studied were normal vulval skin (n = 7), fibroepithelial polyps of vulva (n = 7), vulval smooth muscle neoplasms (n = 5), vulval nerve sheath tumours (n = 2), vaginal angiomyofibroblastoma (n = 1), and pelvic myxoma (n = 1). Nuclear staining was classified as negative, weak, moderate, or strong and the proportion of positively staining cells was categorised as 0, < 10%, 10-50%, or > 50%. Results-All five cases of aggressive angiomyxoma in female patients were positive for ER (two with weak intensity involving < 10% of cells and three with moderate intensity involving 10-50% of cells) and four of five cases were strongly positive for PR in > 50% of cells. The other case was negative for PR. There was no staining with antibodies to ER or PR in the single male patient with aggressive angiomyxoma. Other samples exhibiting positivity of the stromal cells for either ER or PR were normal vulval skin (five of seven, ER; two of seven, PR), fibroepithelial polyps (four of seven, ER; five of seven, PR), smooth muscle neoplasms (three of five, ER; four of five, PR), nerve sheath tumours (one of two, ER; one of two, PR), angiomyofibroblastoma (one of one, ER; one of one, PR), and pelvic myxoma (one of one, PR). Conclusions-All cases of aggressive angiomyxoma of pelvic soft parts in female patients exhibited positivity for ER and/or PR. Because of its propensity to occur in female patients during the reproductive years, it is possible that aggressive angiomyxoma is a hormonally responsive neoplasm. However, dermal fibroblasts in normal vulval skin and stromal cells in a variety of vulval lesions can also be positive. ER or PR immunoreactivity cannot be used to distinguish aggressive angiomyxoma and its histological mimics. (J Clin Pathol 2000;53:603-605)

show abstract

Section: Discussionsupporting

confidence: 54%

mentioning

confidence: 99%

Aggressive angiomyxoma of pelvic parts exhibits oestrogen and progesterone receptor positivity

McCluggage¹,

Patterson²,

Maxwell³

2000

Journal of Clinical Pathology

115

View full text Add to dashboard Cite

show abstract

“…Immunohistochemistry staining for desmin, SMA, vimentin, CD34, S100 protein, and particularly for estrogen and progesterone receptors, is useful [9,10]. In our case, the estrogen and progesterone receptor statuses were positive, and S100 protein was negative, indicative of the typical features of AAM.…”

Section: Discussionmentioning

confidence: 57%

Vulvovaginal aggressive angiomyxoma mimicking lymphedema complicated with Behcet’s disease: a case report and review of the literature

et al. 2012

View full text Add to dashboard Cite

“…Some studies, however, have shown variable staining with desmin [7,9,10,13,14] and focal staining with smooth-muscle actin in a few cases (Table 3) [5,7,[10][11][12][13]. Similar to findings in aggressive angiomyxoma, positive estrogen and progesterone receptor studies have also been reported [13,[15][16][17]. One study demonstrated a few CD34 positive cases [10], whereas no reactivity was seen for this marker in a more recent report [13].…”

Section: Discussionmentioning

confidence: 89%

“…The immunohistochemical profile reported by Fletcher et al [1] indicated that there were sharp differences between these two tumors, but further studies have shown that the immunophenotype of the two tumors can be identical [1,10,13,14]. The matter is still not well defined, and although there are many similarities, the truth is that there are also many differences among them, including clinical and histologic differences (Table 4) [15][16][17][19][20][21][22][23][24][25][26][27][28]. The importance of distinguishing between the two lies in the clearly benign behavior of angiomyofibroblastoma, even when excision shows positive tumor margins.…”

Section: Discussionmentioning

confidence: 99%

Angiomyofibroblastoma

Vasquez

Ro²,

Park

et al. 1999

Int J Surg Pathol

View full text Add to dashboard Cite

We report the clinicopathologic features of eight new cases of angiomyofibroblastoma and review the literature on this recently described entity. Most of our female patients had a vulvar mass that clinically was thought to be a Bartholin's gland cyst. The tumors were well circumscribed and measured 2.9 to 11 cm (mean, 5.2 cm). No recurrences or metastases were observed during follow-up, which ranged from 2 months to 4 years. The tumors were characterized by a myxomatous background with prominent vessels surrounded by plump stromal cells. Immunohistochemically, the stromal cells were reactive for vimentin, but staining for desmin was not always present. Angiomyofibroblastoma should be distinguished from aggressive angiomyxoma because the two entities behave differently. Morphologic and immunohistochemical features should also be considered. Int J Surg Pathol 7(3): [161][162][163][164][165][166][167][168][169] 1999

show abstract

Immunohistochemical analysis of hormone receptors and proliferating cell nuclear antigen in aggressive angiomyxoma of the vulva

Cited by 26 publications

References 10 publications

Aggressive angiomyxoma of pelvic parts exhibits oestrogen and progesterone receptor positivity

Aggressive angiomyxoma of pelvic parts exhibits oestrogen and progesterone receptor positivity

Vulvovaginal aggressive angiomyxoma mimicking lymphedema complicated with Behcet’s disease: a case report and review of the literature

Angiomyofibroblastoma

Contact Info

Product

Resources

About